

IN THE CLAIMS:

Claims 1 has been amended herein. Claims 3 and 4 are canceled herein. Claim 27 is added. This listing of claims replaces all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1. (Currently Amended) A skin care or topical pharmaceutical composition comprising at least a combination of a trypsin inhibitor and an elastase inhibitor and a cosmetically or pharmaceutically acceptable vehicle, and wherein the inhibitors are derived from potato, the inhibitors comprising from 1 to 20 wt.%, based on the total weight of the composition, the composition having a pH range of about 4.8 to about 5.5.

2. (Original) The skin care or topical pharmaceutical composition of claim 1, wherein said cosmetically or pharmaceutically acceptable vehicle is selected from the group consisting of aerosol spray, cream, dispersion, emulsion, foam, gel, lotion, mousse, ointment, pomade, powder, pump spray, solid, aqueous solution, hydro-alcoholic solution and stick.

3.-4. (Canceled).

5. (Original) The skin care or topical pharmaceutical composition of claim 1, further comprising cosmetic adjuncts, pharmaceutical adjuvants or supplements.

6. (Original) The skin care or topical pharmaceutical composition of claim 1 in the form of an aqueous liquid or hydrogel.

7. (Previously Presented) The skin care or topical pharmaceutical composition of claim 1 comprised in a bandage, diaper, patch, towelette or wipe.

8. (Original) The skin care or topical pharmaceutical composition of claim 1 in the form of a lotion that can be absorbed into a bandage, diaper, patch, towelette or wet wipe base sheet.

9. (Previously Presented) The skin care or topical pharmaceutical composition of claim 1 in the form of a hydrogel comprising:

1 to 10 wt.% of the inhibitors from potato;
10-20 wt.% of one or more emollients;
1-5 wt.% of one or more thickeners;
0.1-0.5 wt.% of one or more preservatives; and
water to balance.

10. (Previously Presented) The skin care or topical pharmaceutical composition of claim 1 in the form of an aqueous liquid comprising:

1 to 10 wt.% of the inhibitors from potato;
1-20 wt.% of one or more emollients;
0.5-3 wt.% of one or more thickeners;
0.1-0.5 wt.% of one or more preservatives; and
water to balance.

11. (Previously Presented) The skin care or topical pharmaceutical composition of claim 1 in the form of a rinsing fluid comprising:

1 to 10 wt.% of the inhibitors from potato;
0.8-1.0 wt.% of one or more buffers;
0.1-0.5 wt.% of one or more thickeners; and
water to balance.

12. (Original) The skin care or topical pharmaceutical composition of claim 1 in the form of a Lanette cream having a water content of more than 50%.

13. (Original) The skin care or topical pharmaceutical composition of claim 1 in the form of a "leave-on" product.

14. (Original) An article for topical administration of a skin care or topical pharmaceutical composition comprising, said article comprising:

the skin care or topical pharmaceutical composition of claim 1.

15. (Previously Presented) The article of claim 14, wherein the article is selected from the group consisting of a bandage, diaper, patch, towelette and wipe.

16. (Original) The article of claim 14, wherein the article is of the type having an absorbent portion, said absorbent portion comprising the skin care or topical pharmaceutical composition of claim 1.

17. (Original) The article of claim 16, wherein the article is a cloth or disposable diaper.

18. (Original) The article of claim 14, wherein the article is a wet wipe.

19. (Previously Presented) The article of claim 18, wherein the wet wipe is packed in a pop-up dispenser.

20. (Withdrawn) A method of treating or preventing perineal, peri-anal or peristomal inflammation caused by proteolytic activity of feces in a subject, comprising:

administering, topically, an inhibitor of proteolytic activity derived from a potato to the perineal, peri-anal or peristomal area of the subject, in unit dosage form containing about 0.1 to about 50 g of said inhibitor of proteolytic activity per day.

21. (Withdrawn) The method according to claim 20, wherein the inhibitor of proteolytic activity is administered as an ointment, cream, gel, spray, rinsing fluid or powder.

22. (Withdrawn) The method according to claim 20, wherein a wipe is used to topically administer the inhibitor of proteolytic activity to said subject

23. (Withdrawn) A diagnostic method for studying the effect of an inhibitor of proteolytic activity on inflammatory action of feces, the diagnostic method comprising:
sterilizing feces;
adding at least one proteolytic enzyme to said sterilized feces,
placing a sample of said feces with proteolytic activity on the skin of a healthy subject; and
monitoring the healthy subject skin for inflammatory action.

24. (Withdrawn) The diagnostic method according to claim 23 wherein said feces is taken from an infant or a patient.

25. (Withdrawn) A cloth of woven material to which is chemically associated an inhibitor of proteolytic activity.

26. (Withdrawn) A method to derive protease inhibitors from plants or plant-parts, comprising:
a) grinding the plant or plant parts to a pulp;
b) separating the solids from the pulp to provide a juice of the plant or plant-part;
c) coagulating bulk proteins in said juice, preferably by acidifying and heating of the juice;
d) separating the coagulated proteins from the juice;
e) adjusting the pH to a value of the juice of about 4.0; and
f) isolating the protease inhibitors from the juice by precipitating the protease inhibitors with sodium polyphosphate.

27. (New) A skin care or topical pharmaceutical composition for the alleviation of inflammation caused by proteolytic activity of feces, comprising at least one inhibitor capable of inhibiting proteolytic activity of a protease and a cosmetically or pharmaceutically acceptable vehicle, and wherein the inhibitor is derived from potato.